Objective: The objective was to describe opioid-use trends (2009-2018) at a university hospital emergency department (ED) in metropolitan San Juan, Puerto Rico.
Methods: The ED database of the University of Puerto Rico - Dr. Federico Trilla Hospital provided the data for the study.
Results: Non-fatal opioid overdoses surged 7.5-fold, increasing from 12.1 (±2.5) per 100,000 ED encounters for 2009 through 2016 to 91.2 (±8.7) per 100,000 ED encounters for 2017 through 2018 (P < .0001). Starting in summer 2017, the surge reached its peak in October after two major hurricanes. The opioid-related ED cases comprised 15.8% from 2009 through 2016, increasing to 67% in 2017 through 2018. Prior to October 2015, multiple drugs were mentioned in 65% of the opioid-related cases, decreasing to 37% of the total cases, thereafter. Cocaine was reported in combination with opioids in 53% of all opioid-related cases from August 2009 through September 2015, decreasing to 21% from October 2015 through December 2018, cannabis in 15 % and 10%, respectively, and alcohol in 10% and 6%, respectively. Amphetamines were mentioned once in combination with opioids. The overall male:female ratio for all opioid-related cases was 6.3 (rate: 8.8).
Conclusion: The data show an increase in opioid-toxicity cases in the area served by the above-named hospital beginning in mid-2017. Opioid-related cases overwhelmingly involved male patients. More work is needed to establish islandwide trends.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Managing xylazine-involved overdoses in a community harm reduction setting: lessons from Tijuana, Mexico.
Harm Reduct J
January 2025
Asociación Bajacaliforniana de Salud Pública A.C, Tijuana, Baja California, Mexico.
Background: Xylazine is a α2-adrenergic receptor agonist, used for sedation in veterinary contexts. Although it is increasingly found in overdose deaths across North America, the clinical management of xylazine-involved overdoses has not been extensively studied, especially in community-based harm reduction settings. Here we present a clinical series of xylazine-involved overdose and share the clinical approach and lessons learned by a community overdose response team in Tijuana, Mexico amidst the arrival of xylazine.
View Article and Find Full Text PDFPatient characteristics in relation to opioid exposure in a chronic non-cancer pain population.
Scand J Pain
January 2024
Department of Clinical Sciences Malmö, Center for Primary Health Care Research, Lund University, Jan Waldenströms Gata 35, 202 13 Malmö, Sweden.
Objectives: The efficacy of long-term opioid therapy (LTOT) in treating patients with chronic non-cancer pain (CnCP) is questionable, and the potential risks of adverse effects are well established. The aims were as follows: (1) compare characteristics in patients exposed to LTOT vs non-exposed. (2) Regarding opioid-exposed patients, describe characteristics of patients with risk factors for opioid use disorder or overdose in relation to opioid dosage.
View Article and Find Full Text PDFGenetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study.
Int J Mol Sci
November 2024
Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA.
Opioid use disorder (OUD) affects millions of people worldwide. While it is known that OUD originates from many factors, including social and environmental factors, the role of genetic variants in developing the disease has also been reported. This study aims to investigate the genetic variants associated with the risk of developing OUD upon exposure.
View Article and Find Full Text PDFManagement of patients at risk of harms from both continuing and discontinuing their long-term opioid therapy: A qualitative study to inform the gap in clinical practice guidelines.
Pain Pract
January 2025
San Francisco VA Health Care System, San Francisco, California, USA.
Background: Although long-term opioid therapy (LTOT) for chronic pain has declined, it remains common in the U.S. Providers do not have clinical practice guidelines for vulnerable LTOT patients, in whom both LTOT continuation and tapering to discontinuation pose risks of harm and in whom opioid use disorder (OUD) is absent.
View Article and Find Full Text PDFBuprenorphine 'microdosing' method for switching patients with opioid dependence from methadone to buprenorphine.
BMJ Case Rep
November 2024
National Drug Dependence Treatment Centre, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India
Various factors limit the acceptability of methadone as an opioid agonist treatment (OAT), in which case, buprenorphine becomes the preferred alternative. The classical approach is to gradually taper methadone to a low dose and buprenorphine is initiated after some opioid-free period, which generally takes weeks. A novel approach known as 'microdosing' or the 'Bernese method' might serve as a valuable alternative.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!